Letter Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: What does evidence from randomised trials show about celecoxib? BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7530.1474-c (Published 15 December 2005) Cite this as: BMJ 2005;331:1474 Article Related content Metrics Responses Peer review Related articles Editorial Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Published: 01 June 2002; BMJ 324 doi:10.1136/bmj.324.7349.1287 Primary Care Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis Published: 01 December 2005; BMJ 331 doi:10.1136/bmj.331.7528.1310 Education And Debate How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? Published: 06 October 2005; BMJ 331 doi:10.1136/bmj.331.7520.836 See more Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis BMJ December 05, 2016, 355 i6188; DOI: https://doi.org/10.1136/bmj.i6188 NHS to fund large trial of pre-exposure prophylaxis for HIV prevention BMJ December 05, 2016, 355 i6537; DOI: https://doi.org/10.1136/bmj.i6537 Bill to boost medical research funding and speed drug approval passes US house BMJ December 01, 2016, 355 i6498; DOI: https://doi.org/10.1136/bmj.i6498 Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis BMJ December 01, 2016, 355 i6112; DOI: https://doi.org/10.1136/bmj.i6112 Sixty seconds on . . . solanezumab BMJ November 29, 2016, 355 i6389; DOI: https://doi.org/10.1136/bmj.i6389
